A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson¡¯s disease, in healthy volunteers. (Drug Des Devel Ther. 2019 Mar)
µî·ÏÀÏ
20190419
´Ù¿î·Îµå
Drug Des Devel Ther. 2019 Mar 29;13:1011-1022. doi: 10.2147/DDDT.S198753.